Crispr Therapeutics AG (NASDAQ:CRSP) – Equities research analysts at Oppenheimer issued their Q2 2020 earnings per share (EPS) estimates for Crispr Therapeutics in a research note issued to investors on Tuesday, November 12th, Zacks Investment Research reports. Oppenheimer analyst S. Tuerkcan anticipates that the company will earn ($0.95) per share for the quarter. Oppenheimer currently has a “Outperform” rating and a $80.00 target price on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q3 2020 earnings at ($1.29) EPS and Q4 2020 earnings at ($1.38) EPS.
Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
CRSP has been the subject of several other research reports. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Piper Jaffray Companies reiterated a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a research note on Tuesday. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Tuesday, November 19th. Finally, Canaccord Genuity increased their price target on Crispr Therapeutics from $72.00 to $80.00 and gave the stock a “positive” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $69.54.
CRSP stock opened at $71.65 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. The company has a market capitalization of $3.80 billion, a price-to-earnings ratio of -20.83 and a beta of 3.15. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $74.00. The stock has a fifty day moving average of $49.98 and a 200-day moving average of $46.23.
Institutional investors and hedge funds have recently modified their holdings of the company. BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $39,000. Balyasny Asset Management LLC bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $5,165,000. BNP Paribas Arbitrage SA bought a new stake in shares of Crispr Therapeutics during the 2nd quarter valued at about $41,000. Bank of New York Mellon Corp boosted its position in shares of Crispr Therapeutics by 116.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after acquiring an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Crispr Therapeutics by 34.7% during the 2nd quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after acquiring an additional 701,332 shares during the last quarter. Hedge funds and other institutional investors own 49.81% of the company’s stock.
In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now owns 7,500 shares in the company, valued at approximately $390,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.